TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Pre menopausal female adults with confirmed length and regular menstrual cycle~* Surgically diagnosed endometriosis~* Moderate to severe endometriosis related pain~Exclusion Criteria:~* Hormonal contraceptives or other drugs with effects on gynecological endocrinology~* Surgery for endometriosis within the 4 weeks prior to entry~* Uterine myoma~* Abnormal vaginal bleeding~* Hysterectomy or bilateral oophorectomy~* Pelvic infection~* Relevant abnormalities at gynecological exam at screening~* Disease with chronic abdominal pain of non-endometriosis origin~* Pituitary adenoma

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
- ASP1707 lowest dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- ASP1707 low dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- ASP1707 medium dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- ASP1707 high dose (Type: EXPERIMENTAL): Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
- Leuprorelin acetate (Type: ACTIVE_COMPARATOR): Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection diagnosed according to country testing guidelines~* Age 15-24 years~* Enrolled in care in a study clinic~* Ability and willingness to provide informed consent~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Clinics (Type: EXPERIMENTAL): SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
- Control Clinics (Type: NO_INTERVENTION): Optimized country standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telehealth-Based Exercise Program to Treat Fatigue in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple Sclerosis~* Veteran receiving services in VA VISN 20~* Fatigue~* Ability to ambulate~* cell phone or Household phone line~* Individual with multiple sclerosis verified by MS provider~* ambulatory~Exclusion Criteria:~* Current alcohol dependence or other substance dependence~* No working phone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Brief telephone-based counseling (Type: ACTIVE_COMPARATOR): Telephone based counseling and instructional video
- Education Counseling (Type: PLACEBO_COMPARATOR): Mailed Physical Activity information and instructional video only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Barrow Nasal Inventory Survey

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with planned endonasal surgery for pituitary tumor or skull base lesion~Exclusion Criteria:~* Children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Endonasal surgery (Type: None): Single cohort of patients undergoing endonasal surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, greater than 18 years of age~* Able to understand possible risks and benefits and provide written informed consent (ICF) to the IRB approved clinical multimodal protocol~* LBP with an intensity level of greater than 4 on an eleven point numerical pain rating scale (VRS) of 0-10 (with 0 - no pain and 10 - worst possible pain)~* Completed the necessary diagnostic and medical history evaluations as described in the protocol to confirm the patient's diagnosis and eligibility for the study and DRX9000 treatment protocol.~* Willing and able to complete a six week 20 session of DRX9000 outpatient treatments and a minimum of 6 months follow-up~Exclusion Criteria:~* Pregnancy~* Evidence of neurological motor deficits on clinical examination~* Evidence of spinal cord compression, metastatic cancer, tumor, hematoma, infection or compression fracture~* Evidence of severe central stenosis with neurological deficits or nerve root entrapment~* Litigation for health-related claim (in process or pending), Worker's Compensation, or Personal Injury~* Previous spine fusion surgery, insertion of hardware or artificial disc~* Hemiplegia or paraplegia~* History of severe cardiovascular or metabolic disease, or abdominal aortic aneurysm~* Unwillingness to postpone other types of therapy for LBP during the 6 week treatment sessions~* Known alcohol abuse or drug abuse~* Height less than 4 feet 10 inches (147 cm) or greater than 6 feet 8 inches (203 cm)~* Body weight greater than 300 pounds (136 kg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DRX Group (Type: EXPERIMENTAL): Patients using the device DRX9000™.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective isolated coronary artery bypass surgery with on-pump technique~* Written informed consent~Exclusion Criteria:~* Concomitant valve or aortic surgery~* Left ventricular aneurysm repair~* Re-operation~* Emergency surgery~* History of myocardial infarction within less than 4 weeks~* Hepatic impairment~* Chronic renal impairment~* Drug related side effects (allergy or hypersensitivity)~* Familial Hyperlipidemia~* Autoimmune conditions which require steroids

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Placebo (Type: PLACEBO_COMPARATOR): Atorvastatin like pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to comprehend and follow the requirements of the study (including availability on scheduled visit dates)~2. Male or female of any race or ethnicity, ages 12 and older~3. Diagnosed as having eczema~4. Willing to stop use of all non-assigned moisturizers and/or creams for the entire duration of the study~Exclusion Criteria:~1. Known sensitivity to any investigational product ingredient~2. Females who are pregnant , breastfeeding , or planning on becoming pregnant during the study~3. Individuals with a history of skin cancer~4. Use of a therapeutic (over-the-counter or prescription) body wash that contains an active ingredient for eczema~5. Participation in any clinical study within 30 days of Visit 1~6. Active infection of any type at the start of the study~7. Diagnosed as having severe eczema~8. Has a compromised immune system~9. Individuals with any planned surgeries and/or invasive medical procedures during the course of the study~10. Requires greater than 2.0mg/day inhaled or intranasal corticosteroids

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Positive Control (Type: ACTIVE_COMPARATOR): Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
- Experimental (Type: EXPERIMENTAL): Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for non pregnant women:~* Age ≥18 and ≤ 45 years~* P. falciparum parasitemia ≥ 100 parasites/μL and less than 200.000 parasites/μL~* Hematocrit ≥21%~* Negative HIV test~* Negative pregnancy test\*~* Written informed consent provided~* Willing to stay for 3 or 5 days at the hospital and to comply with the follow-up schedule~Inclusion criteria for pregnant women (in addition to the above criteria except\*):~* Gestational Age ≥ 14 weeks confirmed by ultrasound~* Singleton viable fetus~Exclusion criteria for non-pregnant women:~* Severe malaria or signs of severe malaria~* Medical conditions requiring concomitant drug treatment or transfer to a different hospital~* Intake of artemether-lumefantrine within the two previous 2 weeks~* Known allergy to the study drugs~* Previous participation in this study or current participation in other studies~Exclusion criteria for pregnant women (in addition to the above criteria):~* Signs of labour~* Fetal abnormalities identified by ultrasound

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 3-day artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Standard artemether-lumefantrine regimen (3-day treatment)
- 5-day artemether-lumefantrine (Type: EXPERIMENTAL): Artemether-lumefantrine extended regimen (5-day treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in Post Spinal Anesthesia Shivering

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist class I or II scheduled for elective minor lower abdominal operations under spinal anesthesia for an anticipated duration of \>60 and \<180 min. (e.g. inguinal herniorRaphy, umbilical hernia repair) who developed shivering during the intra or postoperative period~Exclusion Criteria:~* Patients with BMI\>30 kg /m2~* Initial body temperature \>38 C or \<36 C and those with a history of convulsions~* Multiple allergies~* Thyroid disease~* Parkinson's disease~* Dysautonomia~* Raynaud's syndrome~* Hypertension~* Coronary artery disease or other cardio-respiratory or neuromuscular pathology~* Middle ear pathology~* A known history of alcohol use~* Treatment with sedative hypnotic agents or vasodilators~* Having contraindications to spinal anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Pethidine 0.4mg/kg iv (Type: ACTIVE_COMPARATOR): interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
- DEX. I (Type: ACTIVE_COMPARATOR): Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
- DEX. II (Type: ACTIVE_COMPARATOR): Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
- DEX III (Type: ACTIVE_COMPARATOR): Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be male or female and at least 18 years of age.~* Female patients must be of:~* Non-childbearing potential;~* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.~* 4 to 8 AK lesions on non-head locations.~Exclusion Criteria:~* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.~* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.~* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP005 (ingenol mebutate) Gel (Type: ACTIVE_COMPARATOR): PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
- Vehicle gel (Type: PLACEBO_COMPARATOR): Vehicle gel once daily for 2 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age with either type 1 or type 2 diabetes mellitus;~* maximal central subfield foveal thickness (CSF) of at least 300μm (according to SD-OCT images - Spectral Domain Optical Coherence Tomography);~* BCVA of 20 to 80 letters, using ETDRS letters chart;~* ability to provide written informed consent.~Exclusion Criteria:~* Pregnant or lactating;~* Epiretinal membrane (ERM) existence in the study eye;~* persistent posterior hyaloid adherence after vitrectomy for group 2;~* previous vitrectomy for group 1;~* history of other retinal vascular diseases in the study eye;~* LASER photocoagulation or intravitreal injections (IV) of anti-VEGF or systemic anti-VEGF or pro-anti-VEGF treatment and cataract surgery in the 6 months previously to the study eye inclusion;~* IV or peribulbar corticosteroid injections in the 6 months previously to study eye inclusion;~* history of IV of implant of fluocinolone acetonide in the study eye;~* vitreous hemorrhage or opacification in the study eye;~* active proliferative diabetic retinopathy in the study eye;~* active ocular inflammation or infection in either eye;~* aphakia in the study eye;~* other causes for macular edema, for example, after cataract surgery in the study eye;~* other causes of visual loss in the study eye;~* other diseases that may affect the course of macular edema in the study eye;~* uncontrolled glaucoma in either eye (intraocular pressure \> 24 mmHg with treatment);~* history of arterial thrombotic event in the previous 6 months;~* uncontrolled arterial hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \> 100 mmHg);~* ward of the state.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- non vitrectomized eyes (Type: None): ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
- vitrectomized eyes (Type: None): ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with open angle glaucoma or ocular hypertension in both eyes~Exclusion Criteria:~* Patients at risk of progression of visual field loss~* Patients with severe visual field defect~* Patients with any diseases that preclude participation in this study for safety reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 ophthalmic solution (Type: EXPERIMENTAL): None
- Latanoprost ophthalmic solution 0.005% (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Parent Education Program for Early Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant meeting the age criteria~* Access to the internet~* Residence within driving distance of the University of Delaware~* Parental ability to read and communicate in English~Exclusion Criteria:~* Genetic diagnosis~* Progressive diagnosis such as spinal muscular atrophy~* Medical or movement restrictions that would interfere with participation in the study activities

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 1 Year
- Healthy Volunteers: t

Study Arms:
- Baby Play Parent Education Group (Type: EXPERIMENTAL): Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
- Milestone Education Group (Type: ACTIVE_COMPARATOR): Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete